Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease?

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 1, 2007, Pages 83-91

  Stoltey, J ^a   Reeba, H ^a   Ullah, N ^a   Sabhaie, P ^a   Gerson, L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CHRONIC DISEASE; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIGESTIVE TRACT ENDOSCOPY; DISEASE ASSOCIATION; DISEASE COURSE; DYSPEPSIA; DYSPHAGIA; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTOPATHOLOGY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SCREENING; SENSITIVITY AND SPECIFICITY; UPPER GASTROINTESTINAL BLEEDING;

ADULT; AGED; BARRETT ESOPHAGUS; COHORT STUDIES; ENDOSCOPY, DIGESTIVE SYSTEM; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 33845428518     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03138.x     Document Type: Article

References (21)

1. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971-1998. Aliment Pharmacol Ther 2003; 17: 665-76.
2. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett's esophagus correlates with risk of adenocarcinoma. Gastroenterology 2001; 120: 1630-9.
3. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001; 96: 2839-48.
4. Montgomery E, Goldblum JF, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001; 32: 379-88.
5. Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett's esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol 2001; 96: 2005-12.
6. Lieberman DA, Oehlke M, Helfand M, et al. Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. Am J Gastroenterol 1997; 92: 1293-7.
7. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
8. Van Sandick JW, Van Lanschot JJ, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43: 216-22.
9. Sabel MS, Pastore K, Toon H, Smith JL. Adenocarcinoma of the esophagus with and without Barrett's mucosa. Arch Surg 2000; 135: 831-5.
10. van der Burgh A, Dees J, Hop WC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996; 39: 5-8.
11. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000; 321: 1252-5.
12. Etzioni R, Urban N, Ramsey S, et al. The case for early detection. Nat Rev Cancer 2003; 3: 243-52.
13. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002; 122: 26-33.
14. Gerson LB, Triadafilopoulos G. Screening for esophageal adenocarcinoma: an evidence-based approach. Am J Med 2002; 113: 499-505.
15. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett's esophagus in high-risk groups: a cost utility analysis. Ann Intern Med 2003; 138: 176-86.
16. Wilson EB. Probable inference, the law of succession, ad statistical inference. J Am Stat Assoc 1927; 22: 209-12.
17. Practice Parameters Committee ACG, Sampliner RE. Updated guidelines for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2002; 97: 1888-95.
18. Li H, Walsh TN, O'Dowd G, Gillen P, Byrne PJ, Hennessy TP. Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery 1994; 115: 176-81.
19. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the esophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116: 277-85.
20. McDougall NI, Johnston BT, Kee F, Collins JS, McFarland RJ, Love AH. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-6.
21. Gerson LB, Shetler K, Triadafilopoulos G. Prevalence of Barrett's esophagus in asymptomatic adults. Gastroenterology 2002; 123: 461-7.